aleglitazar
Phase 3Small molecule
RocheAleglitazar was being developed to help treat type 2 diabetes by improving how the body uses insulin and manages blood sugar levels.[1] aleglitazar is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
aleglitazar is one of 130 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.
4
Indications
21
Total Trials
0
Active Trials
129
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1aleglitazar
RochePhase 3
Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus9 trials
Show 6 more trials
Type 2 Diabetes3 trials
Tics2 trials
Chronic Kidney Disease1 trial
5 more indications
Cardiovascular Disease1 trial
Hepatic Impairment1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for aleglitazar. EMBL-EBI & Wellcome Sanger Institute.
- [4]